share_log

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

SEC ·  Sep 13 05:14
Summary by Futu AI
180 Life Sciences Corp. has announced an offering of up to 3,296,703 shares of common stock, pre-funded warrants to purchase an equivalent number of shares, and common warrants to purchase up to the same number of shares. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants have an assumed initial exercise price of $1.82 per share, equal to the last reported sales price of the company's common stock on Nasdaq as of September 10, 2024. These common warrants will be exercisable upon obtaining stockholder approval or immediately if certain pricing conditions are met. The offering is being conducted on a 'reasonable best efforts' basis by A.G.P./Alliance Global Partners as the sole placement agent. The company intends to use the net proceeds for research and development expenses, transaction costs to complete a strategic transaction, legal expenses, and working capital. The offering is expected to close on or about the date of the prospectus, subject to customary closing conditions.
180 Life Sciences Corp. has announced an offering of up to 3,296,703 shares of common stock, pre-funded warrants to purchase an equivalent number of shares, and common warrants to purchase up to the same number of shares. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants have an assumed initial exercise price of $1.82 per share, equal to the last reported sales price of the company's common stock on Nasdaq as of September 10, 2024. These common warrants will be exercisable upon obtaining stockholder approval or immediately if certain pricing conditions are met. The offering is being conducted on a 'reasonable best efforts' basis by A.G.P./Alliance Global Partners as the sole placement agent. The company intends to use the net proceeds for research and development expenses, transaction costs to complete a strategic transaction, legal expenses, and working capital. The offering is expected to close on or about the date of the prospectus, subject to customary closing conditions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.